<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01829373</url>
  </required_header>
  <id_info>
    <org_study_id>BG1006</org_study_id>
    <nct_id>NCT01829373</nct_id>
  </id_info>
  <brief_title>Lung Cancer Vaccine Plus Oral Dietary Supplement</brief_title>
  <official_title>Lung Cancer Immunotherapy With Vaccine 1650-G and Yeast Derived β-Glucan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edward Hirschowitz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study tests the ability of the allogeneic cellular vaccine 1650-G vaccine to enhance&#xD;
      immune recognition of tumor cells in patients with lung cancer. The vaccine is combined with&#xD;
      an oral medication called beta glucan, an over the counter oral dietary supplement that may&#xD;
      also stimulate the immune system in ways that helps the body eradicate cancer cells and&#xD;
      reduce risk of recurrent cancer. The primary purpose of this study is to measure the changes&#xD;
      in the number of immune cells that might help lower risk of cancer recurrence. The&#xD;
      investigators do not yet know if the vaccine is effective in fighting cancer and will not&#xD;
      know at the end of this study whether this has been of benefit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label pilot (Phase II) study to assess the immunologic activity of a cellular vaccine&#xD;
      composed of killed allogeneic tumor cells (1650-G) and GM-CSF in patients with stage I-IIIA&#xD;
      NSCLC after definitive therapy. (Surgery, Surgery plus Radiation Therapy, or Surgery,&#xD;
      Radiation Therapy plus Adjuvant Chemotherapy).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunologic response to vaccine</measure>
    <time_frame>12 months</time_frame>
    <description>Increase in number of peripheral blood T cells recognizing cancer antigens</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Vaccine plus oral beta glucan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaccine plus oral beta glucan</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>vaccine 1650-G</intervention_name>
    <arm_group_label>Vaccine plus oral beta glucan</arm_group_label>
    <other_name>Beta Glucan capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven, surgically resected stage I-IIIA NSCLC (Bronchoalveolar&#xD;
             carcinomas are eligible).&#xD;
&#xD;
          -  Must have read, voiced understanding of and signed an informed consent document.&#xD;
&#xD;
          -  At least 21 years old&#xD;
&#xD;
          -  At least 4 weeks but no more than 12 months post surgical resection.&#xD;
&#xD;
          -  At least 4 weeks since completion of chemotherapy or radiation therapy (adjuvant)&#xD;
&#xD;
          -  No evidence of disease following definitive initial therapy evidenced by a CXR, CT or&#xD;
             PET scan within 6 weeks of accrual.&#xD;
&#xD;
          -  ECOG performance status of 0 to 2 (Section 19.1)&#xD;
&#xD;
          -  Adequate organ and marrow function defined as follows:&#xD;
&#xD;
          -  Hemoglobin ≥9.0 gm/dL&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥1,500/mcl&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mcl&#xD;
&#xD;
          -  AST &lt;2.5 x upper limit of normal&#xD;
&#xD;
          -  ALT &lt;2.5 x upper limit of normal&#xD;
&#xD;
          -  Creatinine Clearance (CCr) &gt;50 ml/min&#xD;
&#xD;
          -  Female patients must not be pregnant or breastfeeding. Women of childbearing potential&#xD;
             must have a negative pregnancy test and agree to use acceptable birth control until&#xD;
             the &quot;analysis for immunologic response&quot; 16 weeks after the second vaccination. Study&#xD;
             doctor will discuss acceptable methods of contraception with patients.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients must not have not have no active residual or progressive lung cancer (Stable&#xD;
             Disease)&#xD;
&#xD;
          -  History of other malignancies unless they have had curative treatment completed&#xD;
             greater than (≥) five years prior to enrollment or one of the following; appropriately&#xD;
             managed Carcinoma in situ, basal cell carcinoma of the skin or non-metastatic squamous&#xD;
             cell carcinoma of the skin.&#xD;
&#xD;
          -  Patients must not be chronically immunosuppressed.&#xD;
&#xD;
          -  Patients with HIV and other immunosuppressive disorders and patient who chronically&#xD;
             use immunosuppressive medications are excluded. Patients should not be taking&#xD;
             immuno-suppressive steroids for at least 4 weeks prior to enrollment&#xD;
&#xD;
          -  Individuals with conditions that might require shorter courses of immunosuppressive&#xD;
             oral medications (e.g. steroids) during the initial 16 weeks following immunization&#xD;
             are excluded.&#xD;
&#xD;
          -  Patients should not have taken or plan to take other immunologically active agents (eg&#xD;
             flu vaccines) for a twelve week period, beginning 2 weeks prior to first dose of&#xD;
             beta-glucan and two weeks following last dose of beta glucan.&#xD;
&#xD;
          -  Patients must not have a known history of infectious hepatitis.&#xD;
&#xD;
          -  Because of the unknown effects of this treatment on the fetus pregnant females, and&#xD;
             childbearing females and males not willing to use contraception are not eligible.&#xD;
&#xD;
          -  Patients must not have cardiovascular disease defined as:&#xD;
&#xD;
          -  New York Heart Association Class III or IV congestive heart failure&#xD;
&#xD;
          -  hemodynamically significant valvular heart disease&#xD;
&#xD;
          -  myocardial infarction within the last six months&#xD;
&#xD;
          -  active angina pectoris&#xD;
&#xD;
          -  uncontrolled ventricular arrhythmias&#xD;
&#xD;
          -  stroke within one year&#xD;
&#xD;
          -  known cerebrovascular disease&#xD;
&#xD;
          -  Patients may not have received any other investigational agents or participated in any&#xD;
             investigational drug study within 4 weeks preceding initiation of study treatment.&#xD;
&#xD;
          -  No known allergies or history of allergic reactions to any colony stimulating factor&#xD;
             (GCSF, GMCSF)&#xD;
&#xD;
          -  No known intolerance to yeast derive β-glucan&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Hirschowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Yannelli, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hirschowitz EA, Mullins A, Prajapati D, Baeker T, Kloecker G, Foody T, Damron K, Love C, Yannelli JR. Pilot study of 1650-G: a simplified cellular vaccine for lung cancer. J Thorac Oncol. 2011 Jan;6(1):169-73. doi: 10.1097/JTO.0b013e3181fb5c22.</citation>
    <PMID>21150468</PMID>
  </reference>
  <reference>
    <citation>Hirschowitz EA, Foody T, Hidalgo GE, Yannelli JR. Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer. 2007 Sep;57(3):365-72. Epub 2007 May 16.</citation>
    <PMID>17509725</PMID>
  </reference>
  <reference>
    <citation>Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J. Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol. 2004 Jul 15;22(14):2808-15.</citation>
    <PMID>15254048</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>April 8, 2013</study_first_submitted>
  <study_first_submitted_qc>April 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2013</study_first_posted>
  <last_update_submitted>April 10, 2013</last_update_submitted>
  <last_update_submitted_qc>April 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Edward Hirschowitz</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

